Rocket Pharmaceuticals in-27RCKTWPreferred / convertible
13F holders, Q2 2024 (June 30)14holders −1
1new positions
2sold out
1famous investor
$0.30avg. 13F price*
At the end of Q2 2024, 14 institutions reported holding Rocket Pharmaceuticals in-27 (RCKTW) in their 13F filings, down 1 from Q1 2024. 1 opened new positions and 2 sold out. The largest holders were Boothbay Fund Management, LLC ($795K), Altium Capital Management LLC ($44K) and Walleye Capital LLC ($44K). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- Rocket Pharmaceuticals in-27
- CUSIP
- 77313F114
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $10K |
| Exits | 2 | $22K |
All 13F filers, Q1 2024 → Q2 2024: 176,140 shares bought and 72,098 shares sold, net +104,042 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Boothbay Fund Management, LLC | — | No change | 36,912 | $795K |
| Altium Capital Management LLC | — | No change | 731,561 | $44K |
| Walleye Capital LLC | — | No change | 720,905 | $44K |
| Sio Capital Management, LLC | — | No change | 400,000 | $29K |
| Citadel Advisors | — | Add +1.6% | 370,599 | $22K |
| RTW Investments, LP | — | No change | 350,000 | $21K |
| Fort Baker Capital Management LP | — | No change | 328,698 | $20K |
| Susquehanna International Group, LLP | — | New | 170,364 | $10K |
| Silverarc Capital Management, LLC | — | No change | 104,828 | $6K |
| Affinity Asset Advisors, LLC | — | No change | 75,000 | $5K |
| LMR Partners LLP | — | No change | 60,771 | $4K |
| Walleye Trading LLC | — | No change | 34,829 | $2K |
| Ancora Advisors LLC | — | No change | 6,000 | $364 |
| UBS Group AG | — | Reduce -75.8% | 24 | $1 |
"% of holder's portfolio" is RCKTW's weight in each manager's 13F, not the share of Rocket Pharmaceuticals in-27 the manager owns.